Wegovy Cost Per Month: Four Prices, One Drug

The four Wegovy prices in 2026

Compounded semaglutide is the same active molecule but not Wegovy; it is included because it is the comparison every cash payer ends up making.

Why the $1,349 list price is not your price

Wegovy's list price is the anchor from which rebates and insurance discounts are negotiated. For a cash buyer at a retail counter it produces absurd math: $16,188 a year for a medication whose own manufacturer sells it direct for $5,988. Novo Nordisk's NovoCare program is an explicit acknowledgment that the list price was never meant as a consumer price.

The practical rule is simple: if you are paying anywhere near list for Wegovy, you are in the wrong channel. Either your insurance situation needs to be worked, covered next section, or you should be buying through NovoCare, or you should be comparing the cheaper semaglutide routes ranked in our cheapest semaglutide guide.

The gap has one more practical consequence: pharmacy quotes are not price checks. Calling a retail counter for a Wegovy cash price returns something near list, a number that measures the channel, not the drug. The real quote sheet in 2026 has three lines, copay after prior authorization, $499 direct, and the compounded band, and any decision made without all three lines is made from the wrong menu.

Insurance, prior auth, and the cardiovascular card

When a plan covers Wegovy, the copay typically lands at $25–$50 a month, prior authorization required: documented BMI of 30-plus, or 27 with a comorbidity, often plus a history of weight loss attempts. Many employer plans still exclude weight loss medication outright, and that exclusion, not the copay, is the real obstacle in 2026.

Wegovy holds one card no other weight loss shot has: an FDA-approved indication for cardiovascular risk reduction in adults with established cardiovascular disease and elevated weight. Medicare, which does not cover drugs for weight loss alone, can cover Wegovy under this indication for qualifying patients. If you have cardiovascular history, that reframes the entire prior authorization conversation, and it belongs in any medical necessity letter. The mechanics are covered step by step in the insurance coverage guide.

Employer plans deserve one specific action beyond the formulary check: the benefits team. Weight loss coverage is an employer election, revisited annually, and HR departments track member requests. A short written question, does our plan cover anti-obesity medication, and if not, has adding it been evaluated, costs nothing and registers demand on the side of the benefit. People who assume the answer is fixed miss the year it quietly changes.

NovoCare at $499: the details that matter

For everyone whose plan says no, NovoCare Pharmacy is the benchmark: $499 a month, every dose from 0.25 mg to 2.4 mg, shipped, brand pens. The flat structure means the standard titration schedule, stepping up roughly monthly toward the 2.4 mg maintenance dose, never changes your bill, so a first year is exactly $5,988 plus provider visits.

Constraints worth knowing: it is strictly self-pay and cannot stack with insurance; it requires a valid prescription from a licensed provider; and HSA/FSA funds apply, trimming the effective cost by your tax rate. Against the trial evidence, roughly 15% average body weight loss at 68 weeks in STEP-1, the $499 tier is what most cash payers should measure any alternative against.

The titration schedule gives the flat rate its quiet advantage. Wegovy steps through 0.25, 0.5, 1, 1.7, and 2.4 mg, typically moving up about every four weeks; dose-priced alternatives get more expensive along exactly that path, while NovoCare's bill never moves. It also simplifies the paperwork of a year: one price, twelve shipments, no re-quoting at each dose change, and HSA or FSA cards apply directly, which at typical tax rates brings the effective $499 down into the high $300s in after-tax terms.

When an alternative beats paying for Wegovy

Three comparisons resolve most decisions:

• Vs compounded semaglutide ($99–$299): same molecule, non-brand route, saving $2,400–$4,800 a year over NovoCare. The trade-offs, vial format, 503A framework, are detailed in the compounded vs brand comparison.
• Vs Zepbound ($349–$499 vials): the other approved weight loss shot, with higher average trial results, 20.2% vs 13.7% head-to-head in SURMOUNT-5, at an equal or lower self-pay price. The Wegovy vs Zepbound duel runs that fight in full.
• Vs waiting for a pill: an oral weight loss semaglutide is under FDA review but not approved, with no price; waiting on it is not a strategy.

One number worth memorizing from all of the above: $5,988. That is the honest annual cost of brand Wegovy for a cash payer who does everything right, and every alternative on this page is either an attempt to beat it, compounded at $1,188–$3,588 a year, or a coverage play to replace it with $300–$600 of copays. Framing decisions against that benchmark keeps the comparison grounded.

A licensed provider should weigh in on fit either way. To see current pricing across the self-pay options, compare programs and plans here.